Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Gastroenterol Hepatol. 2013 Feb;11(2):193-5. doi: 10.1016/j.cgh.2012.10.045. Epub 2012 Nov 14.

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Author information

  • 1Vertex Pharmaceuticals, Incorporated, Cambridge, Massachusetts, USA.

Abstract

For patients treated with telaprevir, peginterferon, and ribavirin, futility rules have been developed to prevent needless drug exposure and minimize development of drug-resistant variants for patients who have little or no chance of achieving a sustained virologic response. We performed retrospective analyses of data from phase 3 trials and validated the current futility rule. All therapy should be stopped for treatment-naive and treatment-experienced patients if hepatitis C virus RNA levels are greater than 1000 IU/mL at weeks 4 or 12, or if hepatitis C virus RNA is detectable at week 24.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

PMID:
23159528
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk